The rapid development of modern medicine has significantly extended human life expectancy. However, the prolonged "lifelong disease management period" has become a challenge faced by global society. As life expectancy is no longer the sole measure of health well-being, how to increase healthy life expectancy through scientific interventions has become an urgent issue in the field of healthcare.
Currently, traditional medical systems often exhibit a "reactive" approach, with resources focused on passive management at the downstream stage of diseases. Systematic interventions targeting the "aging process" itself are still lacking in the early stages of life.
Longevity medicine is in a critical phase of transitioning from frontier research to clinical practice. Based on consensus, the industry still needs a practical implementation path.
In order to transform intervention strategies into standardized clinical practices and establish sustainable business models, Shiguangpi has jointly established a collaboration with Frost & Sullivan,to launch the "2026 Global Longevity Medicine Interventions and Business Implementation Guide" compilation project.
We are shifting our research focus from model exploration to standardized "practical guidelines," thoroughly analyzing the technical implementation and service delivery pathways of longevity clinics. Meanwhile, this Guide will rely on Frost & Sullivan and Shiguangpi’s global professional distribution network,to be released simultaneously in Chinese and English, aiming to promote the value recognition of innovative achievements in China’s longevity medicine sector among global capital and cutting-edge academia, and enhance the international influence of local practitioners.
Frost & Sullivan’s overseas website
Shiguangpi’s overseas distribution platform and release cases
Key features of the Guide
This Guide will provide a deep analysis of the current "technical implementation and service delivery" pathways of longevity clinics, including the following key points:
● Global longevity industry map and market size assessment
Integrating global market data, comparing and analyzing the maturity levels and policy access differences of longevity industries in different regions such as the US, Europe, China, and Middle East, and quantifying the real size of the longevity technology market.
● Evolution of MATERNAL AND INFANT anti-aging demands and industry policy environment
Summarizing MATERNAL AND INFANT anti-aging needs, exploring how longevity medicine fills gaps in traditional medicine, focusing on domestic regulatory trends, and outlining the access paths under current compliance frameworks.
● Investment logic and value evaluation system of longevity medicine
Analyzing capital preferences for different technical approaches, establishing an investment evaluation model based on research certainty and commercial potential, and assessing the valuation trends and industrial integration patterns (such as mergers and acquisitions, IPOs) in the longevity sector.
● Systematic classification of aging assessment and intervention technologies
Including complete technical solutions from DNA methylation clocks to regenerative medicine, physical devices, and targeted nutritional supplements.
● Commercial implementation and hierarchical configuration recommendations for longevity clinics
Providing hierarchical configuration models for institutions of various sizes, including specific software and hardware purchase lists, talent allocation, and standard operational processes.
● Case sharing
Using test assessments, core raw materials, and real cases of physical clinics to demonstrate the actual performance of cutting-edge technologies in practice.
Quick overview of the core outline
Related cooperation requirements
To turn visions for future longevity medicine into real, feasible business practices, we are now actively recruiting partner organizations and case studies. The candidates include (but are not limited to):
-
Top-tier hospitals with "longevity/anti-aging" outpatient services, private longevity clinics;
-
High-end health check-up centers or traditional consumer medical institutions seeking business expansion and having initially implemented a "longevity diagnosis and treatment integration" model;
-
High-tech enterprises possessing cutting-edge aging detection technologies (such as multi-omics early screening, DNA methylation, etc.) or aging clock algorithms;
-
Digital SaaS platforms focused on longevity health data management, risk assessment models, and full life cycle follow-up;
-
Core R&D manufacturers in the nutritional supplements market, prescription anti-aging drug market, and bio-based hormones;
-
Producers of anti-aging physical devices (radiofrequency, optoelectronic, hyperbaric chambers), cell therapies, and bio-functional material R&D and application companies;
-
Enterprises whose products, technologies, or services have clear scientific theories and clinical data support, adhering to evidence-based medicine principles;
-
Business delivery models with clear logic, good replicability and scalability, and willing to provide real, non-confidential business practices and operational data as analysis cases.
Participation and contact information
The compilation work of the "Global Longevity Medicine and Clinic Implementation Guide" for this year has been fully launched. We sincerely invite relevant units and high-quality enterprises to participate actively in creating new industry standards.
Whether you are a developer of cutting-edge technologies, a practitioner of rigorous science, or a decision-maker in medical institutions seeking transformation and upgrading, we look forward to your participation. When standards are defined by excellent practitioners, they possess the vitality to lead the industry.
Given the limited length and number of core cases for the Guide, we will conduct a strict evaluation and selection based on the industry representativeness, commercial implementation maturity, and contact order of enterprises.
By becoming a co-constructor, your business model and core technology path will serve as industry benchmark cases, attracting attention from global top capital and high-net-worth clients through the Chinese-English bilingual Guide.
👇 Please scan the QR code below
Add the project business representative
(When submitting applications, please note: "Company Name + Core Business + Guide Co-construction" so we can prioritize your application and send you a detailed cooperation plan)
About LeadLeo:
At the beginning of 2019, LeadLeo (TIMEPIE) was established in Shanghai from its base in Fudan University, focusing on longevity technology. It provides services in aging education, testing, and intervention. It is China’s first media platform dedicated to cutting-edge anti-aging technology and industrial empowerment. Through scientific insights, industrial empowerment, and ecosystem connection, LeadLeo helps Chinese enterprises understand trends, avoid risks, optimize strategies, promote innovative development in aging health industry, and empower the Chinese market.
